First quarter earnings as a potential turning point

Alumis (ALMS) reported first quarter 2026 results that paired sharply lower revenue of US$1.74 million with a narrower net loss of US$93.05 million, drawing investor attention to how the company is funding its pipeline.

The earnings release appears to be a key driver behind recent moves, with the stock posting a 1-day share price return of 1.41% and a 7-day share price return of 3.74%. This comes despite a decline of 10.43% over 30 days and 24.02% over 90 days, while the year to date share price return of 149.36% and the very large 1-year total shareholder return of 401.8% point to strong momentum over a longer stretch.

If Alumis’s recent swing has you thinking about other fast changing opportunities in healthcare and biotech, you may want to scan 34 healthcare AI stocks

With revenue concentrated in early stage programs, a market cap of about US$2.8b and a stock price well below the average analyst target, the key question is simple: is there still a buying opportunity here or is the market already pricing in future growth?

Preferred Price to Book Ratio of 5x: Is it justified?

Alumis is trading on a P/B of 5x, compared with a peer average of 4.4x and a broader US Pharmaceuticals industry average of 2.3x. As a result, the stock is priced at a premium to both its closest peers and the wider sector.

The P/B ratio compares the company’s market value with its net assets on the balance sheet. This can be a useful reference point for early stage, loss making biopharma companies where earnings based metrics are less informative. A higher P/B often suggests investors are willing to pay more than the accounting value of assets, typically because they are focused on future pipeline potential rather than current profitability.

In Alumis’s case, the current premium P/B sits alongside forecasts that revenue could grow 61.8% per year, while the company is still expected to remain unprofitable over at least the next three years. That combination indicates the market is paying up for expected top line expansion and the clinical portfolio, even though current returns on equity are negative and earnings are not projected to turn positive in the near term.

Compared with the peer group average P/B of 4.4x and the wider US Pharmaceuticals industry at 2.3x, Alumis is priced at a substantially higher multiple of its book value. This suggests expectations are set above the sector norm rather than in line with it. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book ratio of 5x (OVERVALUED)

However, the story could change quickly if clinical trial results disappoint or funding needs increase, given the current net loss of US$237.415 million.

Next Steps

With sentiment clearly mixed, and with both risks and rewards in play, it makes sense to review the full picture yourself before forming an opinion. You can quickly weigh both sides by checking the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If Alumis has sharpened your focus, do not stop there. Broaden your watchlist now so you are not late to the next opportunity.

• Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations via the 46 high quality undervalued stocks.
• Strengthen your portfolio’s foundation by focusing on companies with sturdy balance sheets and consistent fundamentals using the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by spotting promising businesses that are still off most investors’ radar through the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.